BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.09
+1.46% today
Updated 2026-04-30
Market cap
$5.37M
P/E ratio
—
P/S ratio
0.72x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
BioNexus Gene Lab Corp Common stock (BGLC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-40.20%
Operating margin
-231.50%
ROE
-35.20%
ROA
-19.70%
Debt/equity
0.03x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | — | $-835.00 | — | — | — |
| 2017 | $107680.00 | $-123750.00 | 73.19% | -118.79% | -114.92% |
| 2018 | $212328.00 | $26454.00 | 13.55% | 28.21% | 12.46% |
| 2019 | $126955.00 | $-246469.00 | 44.02% | -217.17% | -194.14% |
| 2020 | $11.39M | $1.09M | 15.10% | 11.18% | 9.61% |
| 2021 | $13.36M | $751571.00 | 16.42% | 7.90% | 5.62% |
| 2022 | $10.93M | $-355966.00 | 11.52% | -2.66% | -3.26% |
| 2023 | $9.77M | $-2.63M | 13.61% | -26.54% | -26.91% |
| 2024 | $9.51M | $-1.60M | 13.56% | -16.55% | -16.81% |
| 2025 | $7.42M | $-2.98M | 14.62% | -42.54% | -40.20% |